FDA OKs immune-boosting drug for advanced bladder cancer
Share
Tweet
April 30, 2017
TRENTON, N.J. (AP) — U.S. regulators have approved a new drug that harnesses the immune system to treat bladder cancer that has spread after chemotherapy or surgery.
The Food and Drug Administration on Monday approved Imfinzi for advanced bladder cancer, along with a companion diagnostic test for identifying which patients are most likely to benefit from it.
Imfinzi, also known as durvalumab, is part of a new generation of drugs that stimulate the immune system to help fight cancer. British drugmaker AstraZeneca PLC, which developed the drug, is testing it for several other cancers.
The averag...
For access to this article please
sign in or
subscribe.
Reader Comments(0)